NASDAQ$NKTX
Nkarta Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Nkarta reported financial results for the second quarter ended June 30, 2023.
Nkarta reported a net loss of $33.3 million for the second quarter of 2023, with cash and cash equivalents of $302.2 million as of June 30, 2023. The company's cash runway is anticipated to fund operations into 2025. Clinical updates are planned for NKX019 in the second half of 2023 and NKX101 in the first half of 2024.
- NKX101 clinical update highlights encouraging antileukemic activity in patients with AML using fludarabine/cytarabine (Flu/Ara-C) lymphodepletion regimen.
- NKX019 clinical data presented at EHA 2023 and ICML 2023 meetings.
- Clinical updates planned for NKX019 in the second half of 2023 and NKX101 in the first half of 2024.
- Cash and cash equivalents of $302.2 million on June 30, 2023; cash runway anticipated to fund operations into 2025.
Headline financials
Revenue & EPS history
Nkarta · Revenue · Quarterly
$34K
Forward guidance
Nkarta expects its current cash and cash equivalents will be sufficient to fund its current operating plan into 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2023
+0.4%
Avg return
Earnings day
-2.5%
Avg return
5 days after
+1.4%
Avg return
30 days after
61%
14 / 23 earnings
Positive
+16.2%
Q4 2021
Best reaction
-30.3%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.5% | -16.1% | — | |
| Q4 2025 | +0.9% | -0.9% | +37.1% | |
| Q3 2025 | +3.1% | -4.6% | -4.6% | |
| Q1 2025 | +1.2% | -0.6% | -4.6% | |
| Q4 2024 | +3.2% | -15.4% | +13.3% | |
| Q3 2024 | -4.8% | -9.0% | -23.0% | |
| Q2 2024 | +1.2% | +0.0% | +10.3% | |
| Q1 2024 | -2.3% | +2.3% | +3.1% | |
| Q4 2023 | -30.3% | -22.8% | -43.0% | |
| Q3 2023 | -5.6% | +7.0% | +27.0% | |
| Q2 2023 | -0.5% | -1.0% | -20.5% | |
| Q1 2023 | -4.1% | -4.1% | -0.9% | |
| Q4 2022 | +1.3% | -7.1% | +19.3% | |
| Q3 2022 | -8.4% | -2.1% | -35.5% | |
| Q2 2022 | +8.8% | +11.1% | -8.5% | |
| Q1 2022 | +12.8% | +11.1% | +6.9% | |
| Q4 2021 | +16.2% | +6.2% | -15.2% | |
| Q3 2021 | +7.7% | +7.2% | -15.0% | |
| Q2 2021 | -1.9% | -5.0% | -29.0% | |
| Q4 2020 | +0.0% | -14.4% | -30.3% | |
| Q3 2020 | +2.9% | +14.5% | +122.0% | |
| Q2 2020 | -7.0% | -12.0% | +21.1% | |
| Q1 2021 | +11.3% | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro